AMINO III

  • Research type

    Research Study

  • Full title

    An international survey on aminoglycoside practices in critically ill patients: AMINO III survey

  • IRAS ID

    209962

  • Contact name

    Greg Barton

  • Contact email

    greg.barton@sthk.nhs.uk

  • Sponsor organisation

    Nimes University Hospital

  • Duration of Study in the UK

    0 years, 8 months, 31 days

  • Research summary

    The present study is an international observational cohort study on aminoglycosides use in intensive care units. Aminoglycosides are commonly used antibiotics for difficult to treat infections. However, aminoglycosides administration varies widely among countries. The primary objective of this study is to provide up to date and comprehensive descriptive data of the current practices of aminoglycoside use in a large cohort of critically ill\npatients in different countries (Australia, New Zealand, France, UK).The secondary objectives are to describe in a large cohort the variable dosing regimens used, to describe the length of aminoglycoside course, to describe variability in aminoglycoside therapeutic drug monitoring and to describe local ecology. The benefits expected from this study are a better understanding of worldwide aminoglycoside prescription variability in critically ill patients and to determine risk factors of inadequate aminoglycoside dosing regimens. This study will provide useful and specific information on current practices of aminoglycosides and will help to design future studies comparing different aminoglycoside dosing regimens and to determine the optimal aminoglycoside administration for critically ill patients.

  • REC name

    South Central - Hampshire A Research Ethics Committee

  • REC reference

    17/SC/0084

  • Date of REC Opinion

    4 Apr 2017

  • REC opinion

    Further Information Favourable Opinion